Topics in Clinical Biosecurity: Smallpox

Listed below are all CBN articles on Smallpox published since 2005

• 03-13-2018: Modeling Smallpox in 2018: The Role of the Immunosuppressed Population If smallpox ever recurs, the Increasing percentage of immunocompromised Individuals could both amplify the death rate and complicate vaccination strategies.
• 03-06-2015: An Update on Bioterrorism-Related Conditions In the months and early years following these anthrax attacks, the US embarked on the important task of readying the nation for another biological attack
• 05-06-2011: Absence of Smallpox "Take" May Not Indicate Revaccination Failure This study demonstrates that it is not necessary to recall those without a take, even without of evidence at the vaccination site.
• 03-20-2009: 3rd Generation Smallpox Vaccine LC16m8 Proved Safe and Immunogenic The JAMA published a study conducted by a team of Japanese researchers who vaccinated more than 3,000 Japanese military personnel from 2002-2005 with LC16m8.
• 01-08-2009: Update on Smallpox Vaccine In the past few years, there have been several updates to the smallpox vaccine armamentarium. These developments are reviewed below.
• 12-05-2008: Long-lived Immunity after Smallpox Vaccination It has long been held that smallpox vaccination confers 5 to 10 years of protection for recipients, who may then require a booster to maintain immunity.
• 09-07-2007: New Smallpox Vaccine Licensed On September 1, 2007, the U.S. Food and Drug Administration (FDA) announced the approval of ACAM2000TM, a cell based smallpox vaccine.
• 03-27-2007: Contact Vaccinia Reuters reported that a 28 mo. old child developed eczema vaccinatum after contact with his father, a soldier who had been vaccinated with the smallpox vaccine.
• 03-01-2007: Dilution of Smallpox Vaccine, Revisited There are currently three types of smallpox vaccine available for use in the U.S. in the event of a bioterrorism attack.
• 10-23-2006: Smallpox Antiviral Effective in Animal Trials Antiviral drug candidate SIGA-246 demonstrated a high degree of protection against variola, the smallpox virus, in a primate trial conducted at the CDC.
• 12-07-2005: 500,000 Doses of Attenuated Smallpox Vaccine Delivered to U.S. Government The vaccine manufacturing company Acambis was awarded a contract by the NIAID to develop and manufacture a modified Vaccinia Ankara smallpox vaccine.